Cargando…
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials
PURPOSE: Abemaciclib in combination with endocrine therapy (ET) has demonstrated significant efficacy benefits in HR+ , HER2− advanced breast cancer patients in the Phase 3 studies MONARCH 2 (fulvestrant as ET) and MONARCH 3 (letrozole or anastrozole as ET). Here, we report age-specific safety and e...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990838/ https://www.ncbi.nlm.nih.gov/pubmed/33392835 http://dx.doi.org/10.1007/s10549-020-06029-y |
_version_ | 1783669132468682752 |
---|---|
author | Goetz, Matthew P. Okera, Meena Wildiers, Hans Campone, Mario Grischke, Eva-Maria Manso, Luis André, Valérie A. M. Chouaki, Nadia San Antonio, Belén Toi, Masakazu Sledge, George W. |
author_facet | Goetz, Matthew P. Okera, Meena Wildiers, Hans Campone, Mario Grischke, Eva-Maria Manso, Luis André, Valérie A. M. Chouaki, Nadia San Antonio, Belén Toi, Masakazu Sledge, George W. |
author_sort | Goetz, Matthew P. |
collection | PubMed |
description | PURPOSE: Abemaciclib in combination with endocrine therapy (ET) has demonstrated significant efficacy benefits in HR+ , HER2− advanced breast cancer patients in the Phase 3 studies MONARCH 2 (fulvestrant as ET) and MONARCH 3 (letrozole or anastrozole as ET). Here, we report age-specific safety and efficacy outcomes. METHODS: Exploratory analyses of MONARCH 2 and 3 were performed for 3 age groups (<65, 65–74, and ≥75 years). For safety, data were pooled from both studies; for efficacy, a subgroup analysis of PFS was performed for each trial independently. RESULTS: Pooled safety data were available for 1152 patients. Clinically relevant diarrhea (Grade 2/3) was higher in older patients receiving abemaciclib + ET (<65, 39.5%; 65–74, 45.2%; ≥75, 55.4%) versus placebo + ET (<65, 6.8%; 65–74, 4.5%; ≥75, 16.0%). Nausea, decreased appetite, and venous thromboembolic events were all moderately higher in older patients. Neutropenia (Grade ≥ 3) did not differ as a function of age in the abemaciclib + ET arm (<65, 25.8%; 65–74, 27.4%; ≥75, 18.1%). Dose adjustments and discontinuation rates were slightly higher in older patients. Abemaciclib + ET improved PFS compared with placebo + ET independent of patient age, with no significant difference in abemaciclib treatment effect between the 3 age groups (MONARCH 2: interaction p-value, 0.695; MONARCH 3: interaction p-value, 0.634). Estimated hazard ratios ranged from 0.523–0.633 (MONARCH 2) and 0.480–0.635 (MONARCH 3). CONCLUSIONS: While higher rates of adverse events were reported in older patients, they were manageable with dose adjustments and concomitant medication. Importantly, a consistent efficacy benefit was observed across all age groups. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT02107703 (first posted April 8, 2014) and NCT02246621 (first posted September 23, 2014). |
format | Online Article Text |
id | pubmed-7990838 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-79908382021-04-16 Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials Goetz, Matthew P. Okera, Meena Wildiers, Hans Campone, Mario Grischke, Eva-Maria Manso, Luis André, Valérie A. M. Chouaki, Nadia San Antonio, Belén Toi, Masakazu Sledge, George W. Breast Cancer Res Treat Clinical Trial PURPOSE: Abemaciclib in combination with endocrine therapy (ET) has demonstrated significant efficacy benefits in HR+ , HER2− advanced breast cancer patients in the Phase 3 studies MONARCH 2 (fulvestrant as ET) and MONARCH 3 (letrozole or anastrozole as ET). Here, we report age-specific safety and efficacy outcomes. METHODS: Exploratory analyses of MONARCH 2 and 3 were performed for 3 age groups (<65, 65–74, and ≥75 years). For safety, data were pooled from both studies; for efficacy, a subgroup analysis of PFS was performed for each trial independently. RESULTS: Pooled safety data were available for 1152 patients. Clinically relevant diarrhea (Grade 2/3) was higher in older patients receiving abemaciclib + ET (<65, 39.5%; 65–74, 45.2%; ≥75, 55.4%) versus placebo + ET (<65, 6.8%; 65–74, 4.5%; ≥75, 16.0%). Nausea, decreased appetite, and venous thromboembolic events were all moderately higher in older patients. Neutropenia (Grade ≥ 3) did not differ as a function of age in the abemaciclib + ET arm (<65, 25.8%; 65–74, 27.4%; ≥75, 18.1%). Dose adjustments and discontinuation rates were slightly higher in older patients. Abemaciclib + ET improved PFS compared with placebo + ET independent of patient age, with no significant difference in abemaciclib treatment effect between the 3 age groups (MONARCH 2: interaction p-value, 0.695; MONARCH 3: interaction p-value, 0.634). Estimated hazard ratios ranged from 0.523–0.633 (MONARCH 2) and 0.480–0.635 (MONARCH 3). CONCLUSIONS: While higher rates of adverse events were reported in older patients, they were manageable with dose adjustments and concomitant medication. Importantly, a consistent efficacy benefit was observed across all age groups. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT02107703 (first posted April 8, 2014) and NCT02246621 (first posted September 23, 2014). Springer US 2021-01-03 2021 /pmc/articles/PMC7990838/ /pubmed/33392835 http://dx.doi.org/10.1007/s10549-020-06029-y Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Trial Goetz, Matthew P. Okera, Meena Wildiers, Hans Campone, Mario Grischke, Eva-Maria Manso, Luis André, Valérie A. M. Chouaki, Nadia San Antonio, Belén Toi, Masakazu Sledge, George W. Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials |
title | Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials |
title_full | Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials |
title_fullStr | Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials |
title_full_unstemmed | Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials |
title_short | Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials |
title_sort | safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of monarch 2 and 3 trials |
topic | Clinical Trial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990838/ https://www.ncbi.nlm.nih.gov/pubmed/33392835 http://dx.doi.org/10.1007/s10549-020-06029-y |
work_keys_str_mv | AT goetzmatthewp safetyandefficacyofabemaciclibplusendocrinetherapyinolderpatientswithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcanceranagespecificsubgroupanalysisofmonarch2and3trials AT okerameena safetyandefficacyofabemaciclibplusendocrinetherapyinolderpatientswithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcanceranagespecificsubgroupanalysisofmonarch2and3trials AT wildiershans safetyandefficacyofabemaciclibplusendocrinetherapyinolderpatientswithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcanceranagespecificsubgroupanalysisofmonarch2and3trials AT camponemario safetyandefficacyofabemaciclibplusendocrinetherapyinolderpatientswithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcanceranagespecificsubgroupanalysisofmonarch2and3trials AT grischkeevamaria safetyandefficacyofabemaciclibplusendocrinetherapyinolderpatientswithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcanceranagespecificsubgroupanalysisofmonarch2and3trials AT mansoluis safetyandefficacyofabemaciclibplusendocrinetherapyinolderpatientswithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcanceranagespecificsubgroupanalysisofmonarch2and3trials AT andrevalerieam safetyandefficacyofabemaciclibplusendocrinetherapyinolderpatientswithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcanceranagespecificsubgroupanalysisofmonarch2and3trials AT chouakinadia safetyandefficacyofabemaciclibplusendocrinetherapyinolderpatientswithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcanceranagespecificsubgroupanalysisofmonarch2and3trials AT sanantoniobelen safetyandefficacyofabemaciclibplusendocrinetherapyinolderpatientswithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcanceranagespecificsubgroupanalysisofmonarch2and3trials AT toimasakazu safetyandefficacyofabemaciclibplusendocrinetherapyinolderpatientswithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcanceranagespecificsubgroupanalysisofmonarch2and3trials AT sledgegeorgew safetyandefficacyofabemaciclibplusendocrinetherapyinolderpatientswithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcanceranagespecificsubgroupanalysisofmonarch2and3trials |